Regulatory & Market Landscape
from FDA approval to the compounding crisis -- tirzepatide's place in the incretin revolution
The Business of Dual Agonism
Tirzepatide is not just a molecule -- it is the centerpiece of Eli Lilly's growth strategy, a regulatory test case for obesity drug approvals, and the catalyst for a legal battle over compounding pharmacies. Mounjaro and Zepbound together generated over $10 billion in 2024 revenue. Meanwhile, the FDA's decision to remove tirzepatide from the drug shortage list triggered lawsuits from compounders who had been filling demand at a fraction of the brand-name price. This unit covers the regulatory timeline, the compounding controversy, how tirzepatide compares to semaglutide in the market, and the next-generation drugs already in late-stage development.
Competitive Landscape
Compare tirzepatide against other incretin drugs across efficacy, safety, cost, and market positioning.